Essendon, Australia Clinical Trials

A listing of Essendon, Australia clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 234 clinical trials
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

An investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial, to determine the effects of a fixed low-dose combination blood pressure lowering pill ("Triple Pill") on top of standard of care on blood pressure control, and on time to first occurrence of recurrent stroke, in patients with …

systolic blood pressure
telmisartan
stroke
amlodipine
Royal Melbourne Hospital
 (4.2 away) Contact site
  • 399 views
  • 25 Jan, 2021
  • +85 other locations
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Pharmacy Services, Peter MacCallum Cancer Centre
 (3.8 away) Contact site
  • 4293 views
  • 27 May, 2021
  • +497 other locations
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic …

neutrophil count
primary disease
platelet count
systemic disease
remission
The Royal Children's Hospital Melbourne (Pediatrics only)
 (3.2 away) Contact site
  • 70 views
  • 23 May, 2021
  • +76 other locations
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified > 12 months at diagnosis). The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete …

doxorubicin
vincristine
carboplatin
melphalan
cyclophosphamide
Royal Children's Hospital Melbourne
 (3.4 away) Contact site
  • 288 views
  • 26 Jan, 2021
  • +125 other locations
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

somatostatin
radionuclide therapy
measurable disease
progressive disease
edotreotide
Peter MacCallum Cancer Centre
 (5.4 away) Contact site
  • 220 views
  • 19 Apr, 2021
  • +82 other locations
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

renal function tests
mantle cell lymphoma
venetoclax
ibrutinib
cyclin d1
St.Vincent's Hospital
 (5.0 away) Contact site
  • 908 views
  • 06 Mar, 2021
  • +179 other locations
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/L). Approximately 348 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or …

platelet count
polycythemia
blast cells
thrombocythemia
ejection fraction
Alfred Hospital, Malignant Hematology and Stem Cell Transplantation Service
 (5.2 away) Contact site
  • 506 views
  • 15 Jun, 2021
  • +175 other locations
Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden

The purpose of this study is to determine whether FG-4592 is safe and effective in the treatment of anemia in patients with Lower Risk Myelodysplastic Syndrome and Low Red Blood Cell Transfusion Burden.

Investigational Site
 (7.7 away) Contact site
  • 44 views
  • 17 Feb, 2021
  • +74 other locations
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.

DMARD
arthritis
treatment regimen
The Royal Children's Hospital
 (3.2 away) Contact site
  • 294 views
  • 01 Jun, 2021
  • +171 other locations
A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS).

Melbourne Brain Centre Austin Hospital
 (8.6 away) Contact site
  • 112 views
  • 11 May, 2021
  • +114 other locations